Table 2.
SARS-CoV-2 antibodies at baseline, by treatment arm in the modified intention-to-treat population
| Molnupiravir | Placebo | Total | ||||
|---|---|---|---|---|---|---|
| Participants in population | N = 709 | N = 699 | N = 1408 | |||
| Nucleocapsid antibodies | ||||||
| Positive, n (%) | 139 | (19.6) | 151 | (21.6) | 290 | (20.6) |
| Negative, n (%) | 557 | (78.6) | 535 | (76.5) | 1092 | (77.6) |
| Unknowna, n (%) | 13 | (1.8) | 13 | (1.9) | 26 | (1.8) |
| Neutralizing anti-spike antibodies | ||||||
| Positive, n (%) | 190 | (26.8) | 188 | (26.9) | 378 | (26.8) |
| Negative, n (%) | 513 | (72.4) | 506 | (72.4) | 1019 | (72.4) |
| Unknowna, n (%) | 6 | (0.8) | 5 | (0.7) | 11 | (0.8) |
N total number of participants, n number of participants with the corresponding characteristic
aMissing data, invalid sample, tests not done, or results reported as “unknown” are categorized as unknown